S

Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506

Watchlist Manager
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Watchlist
Price: 186.35 CNY -2.73% Market Closed
Market Cap: 74.7B CNY
Have any thoughts about
Sichuan Biokin Pharmaceutical Co Ltd?
Write Note

Sichuan Biokin Pharmaceutical Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sichuan Biokin Pharmaceutical Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Additional Paid In Capital
ÂĄ858.7m
CAGR 3-Years
294%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Additional Paid In Capital
ÂĄ14.1B
CAGR 3-Years
0%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Additional Paid In Capital
ÂĄ1.1B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Additional Paid In Capital
ÂĄ3.2B
CAGR 3-Years
-2%
CAGR 5-Years
14%
CAGR 10-Years
21%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Additional Paid In Capital
ÂĄ17.6B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
30%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Additional Paid In Capital
ÂĄ975.5m
CAGR 3-Years
9%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
No Stocks Found

Sichuan Biokin Pharmaceutical Co Ltd
Glance View

Market Cap
74.7B CNY
Industry
Pharmaceuticals

Sichuan Biokin Pharmaceutical Co Ltd, nestled in the thriving economic landscape of China, is a dynamic force in the pharmaceutical industry. The company has carved a niche for itself by specializing in the production and commercialization of generic and proprietary drugs. Founded on the principles of innovation and accessibility, Biokin has dedicated its resources to the development of a wide range of pharmacological solutions that address both chronic and acute health conditions. Its state-of-the-art manufacturing facilities are complemented by rigorous research and development wings, where scientists and pharmacists collaborate meticulously to forge products that meet the stringent standards of efficacy and safety. At the heart of Sichuan Biokin's business model lies a commitment to affordability and quality, a combination that has enabled it to secure a significant share of the domestic pharmaceutical market. The company capitalizes on the economies of scale, leveraging its expansive production capabilities to reduce costs and enhance profit margins. By strategically aligning with healthcare providers and distributors, Biokin ensures its products efficiently reach hospitals, clinics, and pharmacies across the nation. This extensive distribution network not only enhances accessibility for patients but also cements Biokin’s reputation as a reliable pharmaceutical partner. Meanwhile, its growing portfolio of consumer healthcare products, alongside ongoing investments in biosimilars and more complex drug formulations, positions Biokin to thrive in the ever-evolving global healthcare arena.

Intrinsic Value
48.32 CNY
Overvaluation 74%
Intrinsic Value
Price
S

See Also

What is Sichuan Biokin Pharmaceutical Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
858.7m CNY

Based on the financial report for Dec 31, 2023, Sichuan Biokin Pharmaceutical Co Ltd's Additional Paid In Capital amounts to 858.7m CNY.

What is Sichuan Biokin Pharmaceutical Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
294%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Sichuan Biokin Pharmaceutical Co Ltd have been 294% over the past three years .

Back to Top